Abstract: Early-induced genes by interleukin-2 (IL-2) have various DNA sequences. This patent describes a nucleotide segment, such as SEQ. ID No: 11, SEQ. ID No. 31, or encoding a polypeptide of amino acids 1-159 of SEQ. ID No: 12, antibody binding homologues thereof, antibody binding fragments, and fusion proteins thereof, alleles or naturally occurring mutants of the polyribonucleotides, and anti-sense polyribonucleotides thereof. Also provided are proteins, homologues, fragments, fusion proteins, vectors, transfected hosts, animal models, probes, and other related technology.

Abstract: A human EMAP III polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for preventing and/or treating neoplasia. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.

Abstract: The present invention discloses a novel subfamily of amiloride sensitive sodium channel proteins isolated and purified from the human central nervous system. DNA sequences encoding such proteins are disclosed as are methods and procedures for development of pharmacologic agents for treatment of diseases associated with central nervous system dysfunction.

Abstract: The present invention provides a reagent for extracting lead ions from a variety of biological matrices such as human whole blood that has been anticoagulated with either heparin or EDTA, and lyophilized human blood and bovine EDTA whole blood. The released lead is measured in situ with a colorimetric porphyrin reagent without further manipulation of the supernatant. The lead ion releasing reagent can be used in conjunction with a variety of assay formats for the determination of lead in various biological fluids.

Abstract: The present invention provides novel monocyte activating cytokine (MAC) and a polynucleotide encoding MAC. The invention also provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding MAC. The invention also provides for the production and use of substantially purified MAC in pharmaceutical compositions for the treatment of cancer and disease of the immune system. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding MAC and antibodies which specifically bind to MAC.

Abstract: Early-induced genes by interleukin-2 (IL-2) have various DNA sequences. This patent describes a polyribonucleotide with a nucleotide segment encoding amino acids 1-412 of SEQ. ID No: 14, antibody binding homologues thereof, antibody binding fragments thereof at least 5 amino acids long, and fusion proteins thereof, alleles or naturally occurring mutants of the polyribonucleotide, and anti-sense polyribonucleotides thereof. Also provided are proteins, homologues, fragments, fusion proteins, vectors, transfected hosts, animal models, probes, and other related technology.

Abstract: An alteration in phosphorylation of serine 105, within the activation domain of NF-IL6/LAP, alters its transcriptional efficacy. Polypeptides, polynucleotides and methods of use for modified transcriptional activators allow regulation of gene expression.

Abstract: Early-induced genes by interleukin-2 (IL-2) have various DNA sequences. This patent describes a nucleotide segment encoding a polypeptide including amino acids 1-258 of SEQ. ID No: 10, antibody binding homologues thereof, antibody binding fragments, and fusion proteins thereof, alleles or naturally occurring mutants of the polyribonucleotides, and anti-sense polyribonucleotides thereof. Also provided are proteins, homologues, fragments, fusion proteins, vectors, transfected hosts, animal models, probes, and other related technology.

Abstract: Early-induced genes by interleukin-2 (IL-2) have various DNA sequences. This patent describes a polyribonucleotide with a nucleotide segment encoding amino acids 1-60 of SEQ. ID No: 4, antibody binding homologues thereof, antibody binding fragments thereof at least 5 amino acids long, and fusion proteins thereof, alleles or naturally occurring mutants of the polyribonucleotide, and anti-sense polyribonucleotides thereof. Also provided are proteins, homologues, fragments, fusion proteins, vectors, transfected hosts, animal models, probes, and other related technology.

Abstract: The invention relates to purified proteins induced in human cells by interferon .alpha. or .beta., RNAs, DNAs and hybrid vectors coding for said proteins, hosts transformed with such a hybrid vector, processes for the preparation and purification of these proteins, DNAs, vectors and hosts, monoclonal antibodies specific to these proteins, monoclonal antibody derivatives, hybridoma cell lines secreting these monoclonal antibodies, the use of the monoclonal antibodies and their derivatives in the qualitative and quantitative determination of these proteins, test kits containing the monoclonal antibodies, and pharmaceutical preparations containing said proteins. A protein of the invention shows antiviral properties ascribed to interferons and may be a valuable indicator of the cell response to an interferon therapy.

Abstract: Mammalian G protein coupled glutamate receptors are identified, isolated and purified. The receptors have been cloned, sequenced and expressed by recombinant means. The receptors and antibodies thereby may be used to identify agonists and antagonists of G protein coupled glutamate receptor mediated neuronal excitation, as well as in methods of diagnosis.

Abstract: Disclosed is a retinoic acid receptor epsilon (RAR.epsilon.) polynucleotide and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques and utilizing such polypeptide for therapeutic purposes, for example, tissue regeneration and stimulation of the immune and hematopoietic system. Also disclosed are methods of identifying ligands which stimulate the RAR.epsilon.. Also disclosed are diagnostic methods for detecting a mutation in the RAR.epsilon. receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.

Abstract: The present invention provides a human membrane protein (NHMP1) and polynucleotides which identify and encode NHMP1. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NHMP1 and a method for producing NHMP1. The invention also provides for agonists, antibodies, or antagonists specifically binding NHMP1, and their use, in the prevention and treatment of diseases associated with expression of NHMP1. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NHMP1 for the treatment of diseases associated with the expression of NHMP1. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NHMP1.

Abstract: A transmembrane water channel protein is isolated in highly purified form from human erythrocytes. An identical protein is also found in kidney tubules. cDNA encoding this protein has been isolated and its amino acid sequence determined. cDNA encoding a transmembrane water channel protein has also been obtained from salivary gland, and an identical protein is found in lacrimal gland, cornea, and lung tissue. The amino acid sequence of the protein has been deduced from the cDNA, and the protein has been designated Aquaporin-5. Using the nucleic acid or protein sequence provided herein, the protein may be produced by recombinant DNA techniques. Expression of the protein may be determined by either immunoassay or in situ hybridization assay.

Abstract: An isolated receptor protein for human B cell stimulatory factor-2, capable of specifically binding to the human B cell stimulatory factor-2; DNA coding for the above-mentioned receptor protein; expression vectors containing the above-mentioned DNA; host organisms transformed with the above-mentioned expression vector; a process for production of the receptor protein comprising culturing the host organisms in a medium to produce the receptor protein and recovering the receptor protein from the culture; and a antibody reacting with the protein.

Abstract: Uses for Wnt polypeptides in hematopoiesis are disclosed. In particular, in vitro and in vivo methods for enhancing proliferation or differentiation of a hematopoietic stem/progenitor cell using a Wnt polypeptide, and optionally another cytokine, are described.

Abstract: The present invention concerns a prokaryotic vector which contains a regulatable expression control sequence that can be repressed by the repressor of the tetracycline resistance gene, a prokaryotic cell transformed with this vector and the use of the vector or the cell in a process for the production of polypeptides in prokaryotes by genetic engineering.

Abstract: The present invention is directed to a expression vectors and yeast cells transformed therewith containing a first heterologous nucleotide sequence which codes for a G protein-coupled receptor, for example, the somatostatin receptor, and a second nucleotide sequence which codes for all or a portion of a G protein .alpha..beta..gamma. complex. Said heterologous protein is physically expressed in a host cell membrane in proper orientation for both stereoselective binding of ligands, as well as functional interaction with G proteins on the cytoplasmic side of the cell membrane. In some embodiments, a nucleotide sequence encoding a heterologous or chimeric G.alpha. protein is expressed in conjunction with nucleotide sequences from the yeast G protein .beta..gamma. subunits. A second aspect of the present invention provides expression vectors and transformed yeast cells encoding chimeric yeast/heterologous G protein coupled receptors.

Abstract: The invention provides a human zinc RING protein (ZIRI) and polynucleotides which identify and encode ZIRI. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of ZIRI.

Abstract: The present invention provides a polynucleotide PTEC (prostate expressed chemokine) isolated from a prostate cDNA library which identifies and encodes a novel human rantes homolog PTEC (prostate expressed chemokine). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PTEC. The invention also provides for the therapeutic use of purified PTEC in the treatment of immune deficiency diseases, and for the therapeutic use of antisense molecules, antibodies, antagonists or inhibitors in the treatment of conditions or diseases associated with the expression of PTEC. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, or fragments thereof, or antibodies which specifically bind to the polypeptide.